- Home
- BPT vs AXDX Comparison
BPT vs AXDX Comparison
Compare BPT & AXDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BPT
- AXDX
- Stock Information
- Founded
- BPT 1989
- AXDX 1982
- Country
- BPT United States
- AXDX United States
- Employees
- BPT N/A
- AXDX N/A
- Industry
- BPT Integrated oil Companies
- AXDX Biotechnology: Laboratory Analytical Instruments
- Sector
- BPT Energy
- AXDX Industrials
- Exchange
- BPT Nasdaq
- AXDX Nasdaq
- Market Cap
- BPT 11.7M
- AXDX 13.7M
- IPO Year
- BPT N/A
- AXDX 1996
- Fundamental
- Price
- BPT $0.60
- AXDX $0.15
- Analyst Decision
- BPT
- AXDX
- Analyst Count
- BPT 0
- AXDX 0
- Target Price
- BPT N/A
- AXDX N/A
- AVG Volume (30 Days)
- BPT 108.6K
- AXDX 511.1K
- Earning Date
- BPT 05-20-2025
- AXDX 05-16-2025
- Dividend Yield
- BPT N/A
- AXDX N/A
- EPS Growth
- BPT N/A
- AXDX N/A
- EPS
- BPT N/A
- AXDX N/A
- Revenue
- BPT $236,000.00
- AXDX $11,698,000.00
- Revenue This Year
- BPT N/A
- AXDX $7.25
- Revenue Next Year
- BPT N/A
- AXDX N/A
- P/E Ratio
- BPT N/A
- AXDX N/A
- Revenue Growth
- BPT N/A
- AXDX N/A
- 52 Week Low
- BPT $0.40
- AXDX $0.12
- 52 Week High
- BPT $2.61
- AXDX $2.09
- Technical
- Relative Strength Index (RSI)
- BPT 65.71
- AXDX 15.74
- Support Level
- BPT $0.50
- AXDX $0.12
- Resistance Level
- BPT $0.56
- AXDX $0.56
- Average True Range (ATR)
- BPT 0.03
- AXDX 0.05
- MACD
- BPT 0.01
- AXDX -0.02
- Stochastic Oscillator
- BPT 97.60
- AXDX 5.96
About BPT BP Prudhoe Bay Royalty Trust
BP Prudhoe Bay Royalty Trust is a grantor trust operating in the US. The property of the Trust consists of an overriding royalty interest. The Royalty Interest entitles the Trust to receive the royalty from the production of crude oil and condensate from the working interest of BP Exploration (Alaska) Inc. in the Prudhoe Bay oil field located on the North Slope of Alaska.
About AXDX Accelerate Diagnostics Inc.
Accelerate Diagnostics Inc is an in vitro diagnostics company dedicated to providing solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. Its Clinical Microbiology products include Accelerate Pheno system, Accelerate PhenoTest BC Kit, and Accelerate Arc module & BC kit. The company earns the majority of its revenue from the domestic market. The group operates as one operating segment, deriving instrument, consumable, and service revenues from customers engaged in healthcare diagnostics within the United States. Product revenue is derived from the sale or rental of instruments and sales of related consumable products. Service revenue is derived from the sale of extended service agreements.